Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
In vitro experiments showed that LysoPS inhibits the ILC1 activation in a GPR34-dependent manner via the cAMP-PKA-CREB pathway. Expression knockout of the LysoPS synthase ABHD16A in tumor cells ...
Natural killer (NK) cells constitute a major component of the innate immune response owing to their inherent ability to check the invasion of pathogens without any prior stimulation. NK cells play ...
CULVER CITY, Calif., October 24, 2024--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial ...
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
In vitro experiments showed that LysoPS inhibits the ILC1 activation in a GPR34-dependent manner via the cAMP-PKA-CREB pathway. Expression knockout of the LysoPS synthase ABHD16A in tumor cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback